Pederson v. Novartis Pharmaceuticals Corporation

• Court: District Court, W.D. Washington
• Decided: June 30, 2020
• Docket: 3:20-cv-05216
• Status: Unknown

Opinion

1 HONORABLE RONALD B. LEIGHTON 2 3 4 5

6 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON 7 AT TACOMA 8 CURTIS PEDERSON, CASE NO. 3:20-CV-05216-RBL 9 Plaintiff, ORDER ON DEFENDANT 10 v. NOVARTIS PHARMACEUTICALS CORPORATION’S MOTION TO 11 NOVARTIS PHARMACEUTICALS DISMISS OR FOR MORE DEFINITE CORPORATION, STATEMENT 12 Defendant. 13

14 THIS MATTER is before the Court on Defendant Novartis Pharmaceuticals 15 Corporation’s Motion to Dismiss under Rule 12(b)(6) or, in the alternative, Motion for More 16 Definite Statement under Rule 12(e). Dkt. # 10. Plaintiff Curtis Pederson sued Novartis for an 17 injury he claims to have suffered after taking Novartis’s medication Tasigna to treat his chronic 18 myeloid leukemia. Pederson was diagnosed with leukemia in 2009 and took Tasigna from 2013 19 to 2016. He alleges that Tasigna caused him severe atherosclerotic-related side effects, including 20 coronary artery disease, cerebellar strokes, and peripheral vascular disease. He asserts claims for 21 strict liability – failure to warn and negligence against Novartis. 22 However, what Pederson does not allege is when he first experienced the injuries he 23 seeks to recover for. This is the subject of Novartis’s Motion. Novartis argues that Rule 12(b)(6), 24 ORDER ON DEFENDANT NOVARTIS 1 as interpreted by the Supreme Court, requires Pederson to plead facts related to Novartis’s statute 2 of limitations defense by identifying the date of his initial injury—specifically, his first stroke. 3 Pederson responds that the Ninth Circuit has explicitly held that plaintiffs have no such 4 obligation to address affirmative defenses in the complaint. 5 Dismissal under Fed. R. Civ. P. 12(b)(6) may be based on either the lack of a cognizable

6 legal theory or the absence of sufficient facts alleged under a cognizable legal theory. Balistreri 7 v. Pacifica Police Dep’t, 901 F.2d 696, 699 (9th Cir. 1990). A plaintiff’s complaint must allege 8 facts to state a claim for relief that is plausible on its face. See Ashcroft v. Iqbal, 556 U.S. 662, 9 678 (2009). A claim has “facial plausibility” when the party seeking relief “pleads factual 10 content that allows the court to draw the reasonable inference that the defendant is liable for the 11 misconduct alleged.” Id. The allegations must be “enough to raise a right to relief above the 12 speculative level.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007). On a 12(b)(6) motion, 13 “a district court should grant leave to amend even if no request to amend the pleading was made, 14 unless it determines that the pleading could not possibly be cured by the allegation of other

15 facts.” Cook, Perkiss & Liehe v. N. Cal. Collection Serv., 911 F.2d 242, 247 (9th Cir. 1990). 16 However, a plaintiff “is not required to plead on the subject of an anticipated affirmative 17 defense.” United States v. McGee, 993 F.2d 184, 187 (9th Cir. 1993); see also Pennsylvania 18 State Police v. Suders, 542 U.S. 129, 152 (2004) (plaintiff has no “legal requirement” to plead 19 around affirmative defenses). “Dismissal of claims as barred by the statute of limitations on a 20 Rule 12(b)(6) motion is therefore appropriate only where it is apparent from the face of the 21 complaint that an action will be time barred.” United States v. Sousa, No. 18-CV-03265-EMC, 22 2018 WL 6219803, at *1 (N.D. Cal. Nov. 8, 2018) (quoting Belluomini v. CitiGroup, Inc., No. 23 CV 13-01743 CRB, 2013 WL 3855589, 2013 U.S. Dist. LEXIS 103882 (N.D. Cal. July 23, 24 ORDER ON DEFENDANT NOVARTIS 1 2013)); see also Chubb Custom Ins. Co. v. Space Sys./Loral, Inc., 710 F.3d 946, 974 (9th Cir. 2 2013). 3 The Court must follow this settled precedent, which means Pederson is not required to 4 plead facts related to Novartis’s statute of limitations defense. See Hurd v. Novartis Pharm. 5 Corp., No. 20-CV-262 JAP/GBW, 2020 WL 3101019, at *3-4 (D.N.M. June 11, 2020) (reaching

6 same conclusion in lawsuit based on Tasigna side effects); Tonge v. Novartis Pharm. Corp., No. 7 220CV168FTM38NPM, 2020 WL 3000681, at *2 (M.D. Fla. June 4, 2020) (same). Novartis 8 identifies no case holding that the 12(b)(6) standard described in Twombly and Iqbal extends to 9 affirmative defenses and overrules preexisting case law on the subject. Novartis argues that 10 Pederson should not be allowed to preserve an untimely claim through artful pleading, but this 11 issue would likely be difficult to resolve on a motion to dismiss even if Pederson had alleged that 12 his strokes began around March 2015, as Novartis contends. See, e.g., Stark v. Celotex Corp., 58 13 Wash. App. 940, 943 (1990) (holding, in a product liability action, that “[t]he point at which a 14 plaintiff discovers or should have discovered that he or she is harmed and its cause is a question

15 of fact for the jury to decide”). 16 Aside from the statute of limitations issue, the Court is not convinced that Pederson must 17 allege the date of his first injury to state a plausible claim. While a plaintiff is required to plead 18 “factual content that allows the court to draw the reasonable inference that the defendant is liable 19 for the misconduct alleged,” this does not require a plaintiff to allege every date related to his 20 claim. See Iqbal, 556 U.S. at 678. Novartis cites out-of-circuit cases requiring plaintiffs to allege 21 specific dates related to their injuries, but these cases involve vaguer or more complex 22 complaints and are unpersuasive here. See Coleman v. H.C. Price Co., Civ. Action No. 11-2937, 23 2012 WL 1118775, at *3-4 (E.D. La. Apr. 3, 2012); Slinski v. CSX Transp., No. 07-CV-10270- 24 ORDER ON DEFENDANT NOVARTIS 1 DT, 2007 WL 1377931, at *1 (E.D. Mich. May 8, 2007). Pederson does not allege the date of his 2 first stroke, but he does identify the date he was diagnosed with leukemia, the period during 3 which he took Tasigna, and the specific injuries he experienced because of the drug. He need not 4 allege additional dates to state a plausible claim.1 5 Finally, Novartis is also not entitled to a more definite statement with respect to the date

6 of Pederson’s initial injury. Fed. R. Civ. P. 12(e) allows a party to move for a more definite 7 statement if a pleading is “so vague or ambiguous that the party cannot reasonably prepare a 8 response.” Novartis cites two more out-of-circuit cases in which the court required the plaintiff 9 to clarify dates. MasTec N. Am., Inc. v. Allegiance Commc’ns, LLC, No. 06-02296-JWL, 2006 10 WL 3350712, at *3 (D. Kan. Nov. 17, 2006) (holding that date of contracting was necessary to 11 more speedily address threshold issues, including statute of limitations); Buchholtz v. Renard, 12 188 F. Supp. 888, 892 (S.D.N.Y. 1960) (holding, without explanation, that defendants were 13 entitled to know the dates of stock delivery in securities lawsuit). These cases are non-binding, 14 out of context, and unpersuasive. Pederson’s description of his claims is not vague enough to

15 prevent a response so no more definite statement is required. 16 Novartis claims to possess medical records showing Pederson’s first diagnosed cerebellar 17 stroke occurred around March 2015. See Dkt. # 11, Ex. 1. If Novartis believes this is enough to 18 prove that Pederson’s claims are untimely, it may move for summary judgment on that basis. 19 20 21

22 1 Indeed, Novartis does not contend that Pederson’s Complaint is too vague or conclusory to state a plausible claim. Instead, Novartis’s Motion focuses solely on the statute of limitations 23 issue. But as the Court has already explained, Rule 12(b)(6) does not require a plaintiff to plead facts that overcome affirmative defenses. See McGee, 993 F.2d at 187. 24 ORDER ON DEFENDANT NOVARTIS 1 However, Pederson’s Complaint is not deficient under Rule 12(b)(6) or (e) for failure to include 2 the date of his initial injury. The Motion is DENIED. 3 IT IS SO ORDERED. 4 5 Dated this 30th day of June, 2020.

6 A 7 Ronald B. Leighton 8 United States District Judge

9 10

11 12 13 14 15 16 17 18 19 20 21 22 23 24 ORDER ON DEFENDANT NOVARTIS